Advertisement


Brian I. Rini, MD, on Renal Cell Carcinoma: Exploratory Biomarker Results

2024 ASCO Annual Meeting

Advertisement

Brian I. Rini, MD, of Vanderbilt Ingram Cancer Center, discusses phase III findings of the KEYNOTE-426 study of pembrolizumab plus axitinib vs sunitinib for patients with advanced renal cell carcinoma. He details the exploratory biomarker results, including RNA sequencing, whole-exome sequencing, and PD-L1 (Abstract 4505).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
KEYNOTE-426 was a randomized phase III trial in advanced frontline clear cell kidney cancer that randomized patients to pembrolizumab plus axitinib or sunitinib monotherapy. It was a registration trial that led to FDA approval, and the clinical data has been presented many times showing advantages to the combination arm over monotherapy and response rate, PFS and overall survival. Presented at ASCO as the first translational data from this trial. About 80 or 90% of the patients had baseline tissue that was analyzable. What was analyzed were three main things. One is RNA sequencing, looking at what's called a T-cell inflamed gene expression profile. This is a Merck-derived gene expression profile that basically defines inflammatory or hot tumors. An angiogenesis signature looking at expression of angiogenesis-related genes, and then some other various RNA-seq signatures. DNA alterations were looked at by whole exome sequencing, and what was looked at was the common alterations in kidney cancer like Von Hippel-Lindau and PBRM1 and the like. Then PDL-I staining, which has been reported before, but re-reported here was looked at in terms of the combined positive score. The translational data was linked to the five-year follow-up clinical data presented at ASCO last year and associated with outcome. The main findings were that within the pembo axitinib arm, patients who had higher expression of that T-cell-inflamed GEP, so more inflamed tumors, had better clinical outcomes, not surprisingly. In the sunitinib arm, patients who had higher expression of the angiogenesis-related genes had better clinical outcome. Again, not surprisingly. PDL-I unfortunately was not associated with outcome and it's been a fairly disappointing biomarker in kidney cancer. In terms of the non-GEP, RNA-seq signatures, not much was found. There was some association with a myeloid-derived suppressor cell signature, but it lost significance after adjusting for the T-cell-inflamed GEP, and some of the proliferative signatures were associated with worse outcome, especially in the sunitinib arm. Perhaps not surprisingly; just worse proliferative tumors that don't do as well. In terms of DNA alterations, what was seen is that there really wasn't any consistent association, and this has been seen before with DNA alterations in kidney cancer where there hasn't been good DNA alterations associated with outcome. In this analysis, within the pembro/axi arm, patients who had PBRM1 gene mutant versus wild type had about a 20% improvement in response rate, so there was some difference there. PBRM1 has been looked at in kidney cancer and had sort of variable results, so I think these contribute to those variable results. Then as mentioned, PD-L-I staining, unfortunately, was not really associated with any clinical outcome. In sum, what we see is that patients who have more inflamed tumors do better with the combination. We see higher response rates for the combination across cohorts, but again, it's sort of enriching for response within that patient population. The hard work now is really taking these results and using them prospectively. These results teach us about biology. They teach us about drug mechanism, a lot of which we knew, but I think what we really need to do is design biomarker-based trials that use, I think, baseline RNA-seq results, which I think are the most robust, assign patient's treatment based on that expression or not, and then associate that with outcome. That's how we're really going to move the field forward.

Related Videos

Breast Cancer

Yeon Hee Park, MD, PhD, on Metastatic Breast Cancer: Updated Survival Results of the Young-PEARL Study

Yeon Hee Park, MD, PhD, of South Korea’s Samsung Medical Center and Sungkyunkwan University, discusses phase II findings on palbociclib plus exemestane with a GnRH agonist vs capecitabine in premenopausal patients with hormone receptor–positive, HER2-negative metastatic breast cancer (LBA1002).

Gynecologic Cancers

Yukio Suzuki, MD, PhD, on Endometrial Cancer: Long-Term Survival Outcomes With Hormonal Therapy in Reproductive-Age Patients

Yukio Suzuki, MD, PhD, of Columbia University College of Physicians and Surgeons, discusses data showing that reproductive-age patients with early-stage endometrial cancer who use fertility-preserving hormonal therapy seemed to have good overall survival after a 10-year follow-up (Abstract 5508).

Lymphoma

Peter Riedell, MD, on DLBCL: Expert Commentary on the DEB Study

Peter Riedell, MD, of The University of Chicago, discusses phase III results on the use of tucidinostat plus R-CHOP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) with double expression of MYC and BCL2. The regimen appeared to improve event-free survival and complete response rates vs R-CHOP in the front-line setting. As this is an interim analysis, longer-term follow-up will be needed to better understand its impact, says Dr. Riedell.

Breast Cancer

Sherene Loi, MD, PhD, on Early-Stage Breast Cancer: Weighing the Prognostic Value of ctDNA Detection

Sherene Loi, MD, PhD, of Peter MacCallum Cancer Centre, discusses a circulating tumor DNA (ctDNA) analysis from a cohort of patients with early-stage breast cancer who were enrolled in the monarchE trial. This large cohort was studied to look at the usefulness of a personalized tumor-informed assay for ctDNA detection in early stage high-risk patients (LBA507).

Gynecologic Cancers

Alex Andrea Francoeur, MD, on Endometrial Cancer and Obesity Trends

Alex Andrea Francoeur, MD, of UC Irvine Health, discusses data showing an association between the increasing incidence of endometrial cancer and obesity, which disproportionately affects younger women and women of color. According to Dr. Francoeur, the findings warrant targeted health services and public health interventions to stabilize and ultimately reverse the rising rates (Abstract 5507).

Advertisement

Advertisement




Advertisement